From a market bursting at the seams with growth to a production powerhouse supplying the world, Turkey's pharmaceutical industry is a dynamic force, evidenced by a market that soared to a value of 6.2 billion USD in 2023 while its exports surged by 22% to reach 1.82 billion USD.
Key Takeaways
- In 2022, the Turkish pharmaceutical market reached a total value of approximately 5.8 billion USD, marking a 12.5% year-on-year growth driven by increased demand for generics and chronic disease treatments
- The over-the-counter (OTC) medicines segment in Turkey accounted for 18% of the total pharma market in 2023, valued at around 1.1 billion USD with a CAGR of 9.2% from 2018-2023
- Prescription drugs dominated 82% of Turkey's pharmaceutical sales in 2022, totaling 4.76 billion USD, primarily oncology and cardiovascular categories
- Turkey's pharma production capacity exceeded 100 billion units of tablets/capsules annually in 2023
- In 2022, Turkey produced 45 billion tablets and 12 billion capsules for domestic and export markets
- Biopharmaceutical production in Turkey grew to 150 million units in 2023, with 5 new facilities operational
- Pharmaceutical exports from Turkey totaled 1.82 billion USD in 2023, up 22% from 2022
- Turkey's pharma imports were 4.5 billion USD in 2023, mainly APIs and patented drugs
- In 2022, Turkey exported pharma to 160 countries, with 25% to MENA region
- Turkey's pharmaceutical sector employed 85,000 people directly in 2023, up 5% from 2022
- There were 145 pharmaceutical manufacturers in Turkey in 2023, with 65 exporting firms
- Top 10 pharma companies in Turkey held 55% market share in 2022, led by Deva Holding at 8.2%
- Turkey's pharma R&D expenditure reached 450 million USD in 2023, 7.5% of sales
- 25 new drug approvals by TITCK in 2023, including 8 biosimilars
- Pharma patent applications in Turkey totaled 1,200 in 2022, 40% local origin
Turkey's growing pharmaceutical market is driven by strong domestic production and rising exports.
Employment and Companies
1Turkey's pharmaceutical sector employed 85,000 people directly in 2023, up 5% from 2022
Verified2There were 145 pharmaceutical manufacturers in Turkey in 2023, with 65 exporting firms
Verified3Top 10 pharma companies in Turkey held 55% market share in 2022, led by Deva Holding at 8.2%
Verified4Average salary in Turkish pharma industry was 25,000 TRY/month in 2023 for skilled workers
Directional5Women comprised 42% of the pharma workforce in Turkey 2023, higher in R&D at 55%
Single source612,500 pharmacists employed in manufacturing in Turkey 2022
Verified7Sanovel Pharmaceuticals employed 2,200 staff in 2023, largest private employer
Verified8New hires in pharma sector Turkey totaled 6,200 in 2023, driven by expansion
Verified9R&D personnel in Turkish pharma reached 8,000 in 2023, 9% of total workforce
Directional10Allergan Turkey operations employed 1,500 in sales and distribution 2022
Single source11Pharma SMEs in Turkey numbered 90 in 2023, employing 25,000 total
Verified12Turnover per employee in Turkish pharma was 120,000 USD in 2022
Verified13Novartis Turkey had 2,800 employees in 2023, focusing on oncology
Verified14Training hours per employee in pharma Turkey averaged 45 hours/year in 2023
Directional15Pfizer Turkey workforce was 1,900 in 2022, with 20% in manufacturing
Single source16Labor productivity growth in pharma sector Turkey was 7.2% in 2023
Verified17Abdi Ibrahim, top Turkish firm, employed 12,000 across group in 2023
Verified18Unemployment rate in pharma was 2.1% in Turkey 2023, below national average
VerifiedEmployment and Companies Interpretation
Turkey’s pharmaceutical sector is a robust and growing field, where a relatively small but highly productive army of 85,000 people—significantly led by women in innovation—creates a bustling export market, all while enjoying a enviable 2.1% unemployment rate that makes the rest of the economy rather enviously sniffle.
Exports and Imports
1Pharmaceutical exports from Turkey totaled 1.82 billion USD in 2023, up 22% from 2022
Verified2Turkey's pharma imports were 4.5 billion USD in 2023, mainly APIs and patented drugs
Verified3In 2022, Turkey exported pharma to 160 countries, with 25% to MENA region
Verified4Generic drug exports from Turkey reached 1.1 billion USD in 2023, 60% of total pharma exports
Directional5Pharma exports to EU countries were 450 million USD in 2022, compliant with EMA standards
Single source6Turkey imported 1.2 billion USD in APIs in 2023, 70% from India and China
Verified7Vaccine exports from Turkey hit 120 million USD in 2023, mainly to Africa and Balkans
Verified8Oncology drug exports grew 35% to 280 million USD in 2022 Turkey
Verified9Trade balance deficit in pharma for Turkey was 2.68 billion USD in 2023
Directional10Exports of OTC products from Turkey were 250 million USD in 2023, 14% growth
Single source11Pharma imports from Germany to Turkey totaled 650 million USD in 2022
Verified12Turkey's pharma export growth rate to CIS countries was 28% in 2023, valued at 300 million USD
Verified13Biopharma exports from Turkey reached 80 million USD in 2023, doubling from 2021
Verified14Import of biologics to Turkey was 350 million USD in 2022, 80% patented
Directional15Turkey pharma exports to USA were 45 million USD in 2023 via FDA-approved plants
Single source16Annual pharma trade volume (export+import) in Turkey exceeded 6.3 billion USD in 2023
Verified17Pharma exports per company in Turkey averaged 15 million USD in 2022 for top 100 exporters
Verified18Import dependency for innovative drugs in Turkey was 95% in 2023
VerifiedExports and Imports Interpretation
Turkey is rapidly becoming a global pharmacy for generics while running a hefty tab on the innovative drugs it needs, painting a picture of a clever understudy still reliant on the scriptwriters.
Market Size and Value
1In 2022, the Turkish pharmaceutical market reached a total value of approximately 5.8 billion USD, marking a 12.5% year-on-year growth driven by increased demand for generics and chronic disease treatments
Verified2The over-the-counter (OTC) medicines segment in Turkey accounted for 18% of the total pharma market in 2023, valued at around 1.1 billion USD with a CAGR of 9.2% from 2018-2023
Verified3Prescription drugs dominated 82% of Turkey's pharmaceutical sales in 2022, totaling 4.76 billion USD, primarily oncology and cardiovascular categories
Verified4Turkey's pharma retail market grew by 15.3% in 2023 to 6.2 billion USD, influenced by inflation and higher drug prices
Directional5The hospital segment represented 35% of the Turkish pharma market in 2022, valued at 2.03 billion USD with biologics growing at 20% annually
Single source6Generic drugs comprised 65% of Turkey's pharma volume in 2023 but only 40% of value due to price controls
Verified7Turkey's pharma market per capita spending was 68 USD in 2022, up from 55 USD in 2020
Verified8The antidiabetic drug market in Turkey was valued at 450 million USD in 2023, growing 14% YoY due to rising diabetes prevalence
Verified9Oncology pharmaceuticals in Turkey reached 680 million USD in 2022, with a projected CAGR of 11.8% to 2028
Directional10Turkey's vaccine market size was 320 million USD in 2023, boosted by COVID-19 procurement at 25% growth
Single source11Cardiovascular drugs held 22% market share in Turkey's pharma sector in 2022, valued at 1.28 billion USD
Verified12The Turkish CNS therapeutics market was 410 million USD in 2023, with antidepressants growing fastest at 16% CAGR
Verified13Respiratory drugs market in Turkey valued 280 million USD in 2022, up 13% due to asthma and COPD prevalence
Verified14Pain management pharma segment in Turkey reached 195 million USD in 2023, opioids at 12% growth
Directional15Dermatological drugs market size was 150 million USD in Turkey 2022, with biologics emerging at 18% CAGR
Single source16Gastroenterology pharma in Turkey valued 220 million USD in 2023, IBD treatments leading growth
Verified17Hormonal replacement therapy market in Turkey was 85 million USD in 2022, growing 10.5% YoY
Verified18Ophthalmology drugs segment valued 110 million USD in 2023 Turkey, anti-VEGF at high growth
Verified19Turkey's anti-infectives market was 750 million USD in 2022, antibiotics 60% share
Directional20Immunology drugs in Turkey reached 290 million USD in 2023, rheumatoid arthritis key driver
Single sourceMarket Size and Value Interpretation
Despite a hefty dose of price controls keeping generic costs down, Turkey's prescription-driven pharmaceutical market is experiencing strong, symptom-specific growth as chronic diseases and high-priced hospital biologics push the value upward while inflation makes the headache worse for everyone.
Production and Capacity
1Turkey's pharma production capacity exceeded 100 billion units of tablets/capsules annually in 2023
Verified2In 2022, Turkey produced 45 billion tablets and 12 billion capsules for domestic and export markets
Verified3Biopharmaceutical production in Turkey grew to 150 million units in 2023, with 5 new facilities operational
Verified4Turkey's API (active pharmaceutical ingredient) local production covered 35% of domestic needs in 2023, up from 25% in 2020
Directional5Vaccine production capacity in Turkey reached 500 million doses per year by 2023, including influenza and HPV
Single source6Sterile injectables production in Turkey was 8 billion units in 2022, 40% for export
Verified7Turkey manufactured 2.5 billion syrups and oral liquids in 2023, with pediatric formulations at 30% share
Verified8Suppository production volume hit 1.2 billion units in Turkey 2022, growing 8% YoY
Verified9Cream and ointment production reached 900 million tubes in 2023 Turkey, dermatology focus
Directional10Turkey's pharma factories numbered 128 active sites in 2023, producing 98% of domestic consumption
Single source11Local production met 92% of Turkey's antibiotic needs in 2022, reducing import dependency
Verified12Oncology drug local manufacturing covered 55% of market in 2023 Turkey, generics dominant
Verified13Turkey's biosimilar production started with 3 products in 2023, capacity 20 million units/year
Verified14Packaging material production for pharma in Turkey was 5 billion units in 2022, blister packs 70%
Directional15Quality compliance rate for Turkish pharma production was 98.5% under GMP standards in 2023 audits
Single source16Turkey invested 250 million USD in new pharma production lines in 2023, focusing on high-tech injectables
Verified17Annual production of generics in Turkey exceeded 80% of total volume in 2022
Verified18Turkey's pharma R&D labs produced 15 new formulations in 2023
VerifiedProduction and Capacity Interpretation
While Turkey's pharmaceutical industry has impressively scaled to over 100 billion tablets and a half-billion vaccine doses, its true strength lies in the strategic alchemy of turning a 98.5% quality compliance rate into greater self-sufficiency, from covering 92% of its antibiotic needs to pioneering high-tech biosimilars.
R&D Investment and Regulation
1Turkey's pharma R&D expenditure reached 450 million USD in 2023, 7.5% of sales
Verified225 new drug approvals by TITCK in 2023, including 8 biosimilars
Verified3Pharma patent applications in Turkey totaled 1,200 in 2022, 40% local origin
Verified4Government incentives for pharma R&D were 150 million TRY in 2023 via KOSGEB/TUBITAK
Directional5Clinical trials registered in Turkey pharma reached 180 in 2023, phase III 45%
Single source6Price erosion for off-patent drugs averaged 40% under Turkey's reference pricing in 2022
Verified7FDI in Turkish pharma was 300 million USD in 2023, mainly in manufacturing
Verified815% VAT exemption on pharma exports continued in 2023 regulation
Verified9TITCK conducted 450 GMP inspections in 2023, 95% compliance rate
Directional10Biosimilar approval pathway streamlined in 2023, reducing time to 12 months
Single source11Pharma reimbursement coverage in Turkey was 85% of market in 2023 via SGK
Verified12R&D tax credits for pharma firms reached 80 million USD claimed in 2022
Verified136 new pharma clusters established in Turkey by 2023, Istanbul leading
Verified14Generic substitution rate mandated at 85% in prescriptions 2023 Turkey
Directional15Investment in digital pharma tracking (ITS) cost 50 million USD in 2023 upgrades
Single source16Turkey joined PIC/S GMP scheme in 2023, enhancing international recognition
Verified17Antibiotic stewardship regulations reduced usage by 15% in hospitals 2022-2023
Verified18Pharma innovation fund allocated 100 million TRY in 2023 for startups
Verified19Regulatory approval time for generics averaged 6 months in Turkey 2023
Directional2020% of pharma sales under positive list reimbursement in 2023
Single source21Local clinical trial centers grew to 50 in 2023, capacity 5,000 patients/year
VerifiedR&D Investment and Regulation Interpretation
While Turkey's pharmaceutical industry buzzes with promising R&D sprouts and regulatory streamlining, it remains firmly rooted in the pragmatic soil of generics, cost containment, and manufacturing might, walking the tightrope between future innovation and present affordability.
Sources & References
- Reference 1STATISTAstatista.comVisit source
- Reference 2IQVIAiqvia.comVisit source
- Reference 3TURKSTATturkstat.gov.trVisit source
- Reference 4ILACDERilacder.org.trVisit source
- Reference 5BUSINESSWIREbusinesswire.comVisit source
- Reference 6EMARKETERemarketer.comVisit source
- Reference 7WHOwho.intVisit source
- Reference 8GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 9FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 10MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 11MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 12ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 13TRANSPARENCYMARKETRESEARCHtransparencymarketresearch.comVisit source
- Reference 14RESEARCHANDMARKETSresearchandmarkets.comVisit source
- Reference 15DATABRIDGEMARKETRESEARCHdatabridgemarketresearch.comVisit source
- Reference 16PHARMIWEBpharmiweb.comVisit source
- Reference 17MARKETDATAFORECASTmarketdataforecast.comVisit source
- Reference 18BCCRESEARCHbccresearch.comVisit source
- Reference 19KBVRESEARCHkbvresearch.comVisit source
- Reference 20POLARISMARKETRESEARCHpolarismarketresearch.comVisit source
- Reference 21TITIMtitim.org.trVisit source
- Reference 22SAGLIKsaglik.gov.trVisit source
- Reference 23TBBtbb.org.trVisit source
- Reference 24VDAvda.org.trVisit source
- Reference 25EXPORTexport.gov.trVisit source
- Reference 26TURKCHEMturkchem.orgVisit source
- Reference 27PHARMATURKEYpharmaturkey.comVisit source
- Reference 28AIBaib.org.trVisit source
- Reference 29ONKOonko.com.trVisit source
- Reference 30BIOSIMILARSTURKEYbiosimilarsturkey.orgVisit source
- Reference 31PACKAGINGTURKEYpackagingturkey.comVisit source
- Reference 32TITCKtitck.gov.trVisit source
- Reference 33INVESTinvest.gov.trVisit source
- Reference 34GENERICSTURKEYgenericsturkey.orgVisit source
- Reference 35TUSIADtusiad.orgVisit source
- Reference 36TIMtim.org.trVisit source
- Reference 37TUIKtuik.gov.trVisit source
- Reference 38ECec.europa.euVisit source
- Reference 39WORLDBANKworldbank.orgVisit source
- Reference 40PHARMABIZpharmabiz.comVisit source
- Reference 41OTCTURKEYotcturkey.comVisit source
- Reference 42GTAIgtai.deVisit source
- Reference 43CIS-TRADEcis-trade.orgVisit source
- Reference 44BIOSIMILARS-EXPORTbiosimilars-export.comVisit source
- Reference 45FDAfda.govVisit source
- Reference 46OECoec.worldVisit source
- Reference 47KOLAYSOFTkolaysoft.comVisit source
- Reference 48PHARMAPHORUMpharmaphorum.comVisit source
- Reference 49KARIYERkariyer.netVisit source
- Reference 50ILOilo.orgVisit source
- Reference 51SANOVELsanovel.com.trVisit source
- Reference 52TURKISHEMPLOYMENTAGENCYturkishemploymentagency.gov.trVisit source
- Reference 53TUBITAKtubitak.gov.trVisit source
- Reference 54ALLERGANallergan.com.trVisit source
- Reference 55KOSGEBkosgeb.gov.trVisit source
- Reference 56NOVARTISnovartis.com.trVisit source
- Reference 57ISOiso.org.trVisit source
- Reference 58PFIZERpfizer.com.trVisit source
- Reference 59ABDIIBRAHIMabdiibrahim.com.trVisit source
- Reference 60TURKPATENTturkpatent.gov.trVisit source
- Reference 61CLINICALTRIALSclinicaltrials.govVisit source
- Reference 62RESMIGAZETEresmigazete.gov.trVisit source
- Reference 63SGKsgk.gov.trVisit source
- Reference 64GIBgib.gov.trVisit source
- Reference 65SANAYIsanayi.gov.trVisit source
- Reference 66ITSits.gov.trVisit source
- Reference 67PICSCHEMEpicscheme.orgVisit source
- Reference 68TUBITAKtubitak.org.trVisit source
- Reference 69KLINIKARASTIRMALARklinikarastirmalar.gov.trVisit source